Clinical Study Coverage Highlights Performance of Vektor Medical’s vMap in Ventricular Tachycardia

A LinkedIn post from Vektor Medical Inc highlights coverage in EP Lab Digest of clinical data from an EP Europace study evaluating vMap-guided activation mapping and ablation in patients with hemodynamically unstable ventricular tachycardia. According to the post, vMap is described as a non-invasive technology that applies computational algorithms to standard 12-lead ECG data to localize arrhythmia sources.

The post indicates that the study reported identification of ventricular tachycardia origin in under 30 seconds, which is presented as reducing VT duration while preserving diagnostic information for mechanistic mapping. Reported data points include 80% arrhythmia-free survival at one year, 37% acute VT termination, rapid localization in under 30 seconds, and no observed increases in procedure or fluoroscopy time or procedural risk.

For investors, the post suggests growing clinical validation and visibility of vMap within the electrophysiology community, which could support adoption in complex ventricular tachycardia cases. If these performance metrics are replicated at scale and translate into workflow efficiencies and improved outcomes, Vektor Medical could strengthen its competitive position in cardiac mapping solutions and potentially expand its addressable market in cardiology and ablation procedures.